Format

Send to

Choose Destination
Nat Genet. 2014 Jun;46(6):595-600. doi: 10.1038/ng.2969. Epub 2014 May 4.

A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations.

Author information

1
1] Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA. [2] Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA. [3].
2
1] Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA. [2].
3
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
4
Genomics Core Laboratory, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
5
Bioinformatics Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
6
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
7
Department of Pathology, University Hospital Gasthuisberg and University of Leuven, Leuven, Belgium.
8
Department of Pathology, University of Nebraska Medical Center, Omaha, Nebraska, USA.
9
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
10
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
11
Laboratory of Pathology, National Cancer Institute, Bethesda, Maryland, USA.
12
Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
13
1] Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA. [2] Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

Abstract

Rhabdomyosarcoma, a cancer of skeletal muscle lineage, is the most common soft-tissue sarcoma in children. Major subtypes of rhabdomyosarcoma include alveolar (ARMS) and embryonal (ERMS) tumors. Whereas ARMS tumors typically contain translocations generating PAX3-FOXO1 or PAX7-FOXO1 fusions that block terminal myogenic differentiation, no functionally comparable genetic event has been found in ERMS tumors. Here we report the discovery, through whole-exome sequencing, of a recurrent somatic mutation encoding p.Leu122Arg in the myogenic transcription factor MYOD1 in a distinct subset of ERMS tumors with poor outcomes that also often contain mutations altering PI3K-AKT pathway components. Previous mutagenesis studies had shown that MYOD1 with a p.Leu122Arg substitution can block wild-type MYOD1 function and bind to MYC consensus sequences, suggesting a possible switch from differentiation to proliferation. Our functional data now confirm this prediction. Thus, MYOD1 p.Leu122Arg defines a subset of rhabdomyosarcomas eligible for high-risk protocols and the development of targeted therapeutics.

PMID:
24793135
PMCID:
PMC4231202
DOI:
10.1038/ng.2969
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center